• Do you know your owners’ preference when it comes to long-term OA management?
• A survey conducted in 2023 of over 2,000 dog owners concluded that 7 out of 10 would prefer a weekly dosing regime over a daily one¹.

• How often are you asking your clients what their preferred method of treatment is?

In a 6-month study , performed in client-owned dogs with naturally occurring OA:

Reported initial adverse events were short in duration and the incidence rate had no tendency to increase
over time (common adverse events involved the GI system, which typically resolved on their own, as is common with all NSAIDs).

No relevant changes in haematology, biochemistry or urine parameters were seen in longer-term cases.

Enflicoxib’s (Daxocox) safety profile is maintained in long-term treatment, making it a good choice for chronic treatment in dogs with OA.

• The only, once-weekly, first-line NSAID for all stages of OA
• COX-2 selective inhibition with a unique mode of action
• Consistent seven-day pain relief
• No over-accumulation – no treatment breaks needed